Extended-release injectable suspension naltrexone (XR-NTX) as an adjunct pharmacotherapy for prevention of substance use in SUD patients who are currently in treatment for ADHD
We use cookies to keep your session secure, remember your preferences, and analyse site traffic with Google Analytics.
By continuing to use GrantFunds you agree to our
Privacy Policy
and
Terms of Use.